Investigation Report on China Doxofylline Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||332770|
|出版日期||內容資訊||英文 30 Pages
|Doxofylline的中國市場分析 (2010∼2019年) Investigation Report on China Doxofylline Market, 2010-2019|
|出版日期: 2015年06月11日||內容資訊: 英文 30 Pages||
Doxofylline是支氣管氣喘的治療藥 (抗支氣管痙攣劑) 的一種，1988年義大利開始上市。1992年也在中國上市，現在已有提供各種劑型 (糖漿，藥丸，注射藥，API (原料藥) 及其他) 。中國國內Doxofylline的市場規模，在2010年為1億2400萬人民幣，2014年2億2400萬人民幣，2010∼2014年的年複合成長率(CAGR) 達到了15.9％。
With the climatic and environmental changes, seasonal asthma has become the main reason for respiratory ailments. According to an epidemiological survey, the incidence of respiratory ailments is 16% of the incidence of all diseases. About 280 million people in the world suffer from different degrees of seasonal asthma. The situation is more serious in industrialized countries and regions where tobacco consumption is high with 5% of adults and 20% of children there having been attacked by this disease. Nearly 300 million people in China contract respiratory ailments, among which over 50 million suffer from cough with an annual growth rate of 4% and 15-20 million asthma.
Doxofylline, a derivative of theophylline, is a methylxanthine anti-bronchospasm drug for the treatment of bronchial asthma, panting chronic bronchitis and breathing difficulties caused by other bronchospasm. It is also a common drug for acute and chronic obstructive airway disorders. Unlike other methylxanthines, dexofylline has no side effects on gastrointestinal tract, nervous system, heart and kidney. First developed and marketed by ITALY and ABC company in 1988, doxofylline has now become the best-selling drug in many countries like the US, Japan, Ireland and Canada. Chinese enterprises begun manufacturing improvements in 1992 and has now developed such dosage forms as syrup, tablet, injection and APIs. Compared with traditional theophylline and aminophylline, doxofylline has better efficacy and less toxicity and therefore is worthwhile for spreading in clinical practice.
Doxofylline develops fast after entering China, annual sales value rising from CNY 124 million in 2010 to CNY 224 million in 2014 and CAGR reaching up to 15.9% during the period of 2010-2014. Doxofylline enjoys a vast demand in China. Currently, Fuhe Huaxing Pharmaceutical Shares Co., Ltd, Xi'an Bosen BioPharma Co., Ltd, Zhejiang Hansheng Pharmaceutical Co., Ltd of Beisheng Pharma, Kaifeng Canon Pharmaceutical Co., Ltd and ReYoung Pharmaceutical Co., Ltd all take up certain shares in the market, among which Fuhe Huaxing Pharmaceutical Shares Co., Ltd has the largest market share of 27.8% with sales value in 2014 reaching up to CNY 62.33 million.
As environmental pollution worsens in China, the incidence of respiratory ailments will keep growing. Therefore, the market size of doxofylline in China is expected to keep expand in the next few years.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report: